Table 1 - BMJ



Table 1. Price comparison of selected medicines for common and rare indications in Belgium in 2011

1A. Comparison based on DDD

|INN |Medicine for common disease |Medicine for rare indication |Year of |Year of orphan |

| | | |evidence |designation |

| |Trade name |DDD |Form |Price per DDD (€)|

| | | | | |

| | | | | |

|Trade name |Dose

|Form

|Price per dose (€) |Trade name |Dose

|Form

|Price per dose

(€) | | | |Caffeine |Coffeine |250 mg |inj |0.50 |Peyona |10 mg |inj |19.73 |1975 |2002 | |Hydroxycarbamide |Hydrea |500 mg |caps |0.44 |Siklos |1000 mg |caps |25.51 |1987 |2003 | |Thiotepa |Ledertepa |15 mg |inj |35.3 |Tepadina |100 mg |inj |810.00 |1968 |2007 | |Busulfan |Myleran |2 mg |caps |0.14 |Busilvex |60 mg |inj |305.00 |1988 |2000 | |Notes:

- ‘DDD’ = defined daily dose; ‘INN’ = international non-proprietary name; ‘inj’ = injection; ‘caps’ = capsules; ‘inf’ = infusion.

- Xenbilox and Adcirca did not apply for an orphan designation.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download